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The motherhood choices decision aid for
women with rheumatoid arthritis increases
knowledge and reduces decisional conflict:
a randomized controlled trial
T. Meade1,2*, E. Dowswell1, N. Manolios2 and L. Sharpe3
Abstract
Background: For many women with Rheumatoid Arthritis (RA) motherhood decisions are complicated by their
condition and complex pharmacological treatments. Decisions about having children or expanding their family
require relevant knowledge and consultation with their family and physician as conception and pregnancy has to
be managed within the RA context. Relevant information is not readily available to women with RA. Therefore a
randomized controlled study was conducted to evaluate the effectiveness of a new motherhood decision aid (DA)
developed specifically for women with RA.
Methods: One hundred and forty-four women were randomly allocated to either an intervention or control group.
All women completed a battery of questionnaires at pre-intervention, including, the Pregnancy in Rheumatoid
Arthritis Questionnaire (PiRAQ), the Decisional Conflict Scale (DCS), the Hospital Anxiety and Depression Scale
(HADS), and the Arthritis Self-Efficacy Scale (ASES), and provided basic demographic information. Women in the DA
group were sent an electronic version of the DA, and completed the battery of questionnaires for a second time
post-intervention.
Results: Women who received the DA had a 13 % increase in relevant knowledge (PiRAQ) scores and a 15 %
decrease in scores on the decisional conflict (DCS), compared to the control group (1 %, 2 % respectively). No
adverse psychological effects were detected as evident in unchanged levels of depression and anxiety symptoms.
Conclusions: The findings of this study suggest that this DA may be an effective tool in assisting women with RA
when contemplating having children or more children.
Trial registration: Australian New Zealand Clinical Trials Registry, http://www.anzctr.org.au/, ACTRN12615000523505.
Background
The decision to have children is influenced by a number
of factors including relationship quality and readiness,
education level, financial considerations, and the avail-
ability of social support [1–3]. Women with chronic
medical conditions may experience additional challenges
associated with their health care needs, social stigma
pertaining to their parenting capacity, and the impact of
their condition on pregnancy and motherhood [4–7].
While parenting is generally accepted as a positive ex-
perience, for many women with chronic conditions such
as Rheumatoid Arthritis (RA), the physical symptoms
can significantly impair their role and performance as
mothers [8–10]. Some women experience feelings of guilt
and shame over the impact of their illness on parenting
and have to adjust their expectations of themselves as
mothers [11, 12].
RA is a chronic, autoimmune disease that occurs three
times more frequently in women than men and may
affect women during their childbearing and childrearing
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years [13, 14]. Given the early onset of RA and the high
prevalence rates in women, reproductive health is a rele-
vant concern for patients and health professionals [15].
Furthermore, living with RA in the first few years after
diagnosis can be challenging, [16] and may coincide with,
and have important implications for, family planning [11].
There is a longstanding link between RA and infertility
with the incidence of nulliparity in women with RA greater
than those without the disease [17]. However, lower birth
rates may be due to: (i) reduced sexual function [18], (ii) de-
ciding not to have a family, or to have smaller families due
to concerns about the impact of RA or its treatment on the
foetus [16, 17], or the perception of pregnancy as being
risky [19], (iii) fear of transmitting the disease to the child
[20]; and (iv) perceived lack of support from their health
professionals [12].
It is well established that pregnancy and childbirth can
affect the disease activity of RA [21]. During pregnancy
a decision to limit the use of RA medication may be made
because of the risks that pharmacological treatments can
pose to the foetus. However, reduced uptake of disease
modifying drugs may lead to increased disease activity in
the mother [22]. The development of various biological
pharmacotherapies for RA has, for women with RA, sup-
ported increased physical capability to manage pregnancy
and overcome challenges of raising children [23]. However
these therapies may concern women and compound the
complexity of their motherhood decision [11].
For women with RA there are some risks associated
with pregnancy. While remission can spontaneously occur
during pregnancy [24–26] RA symptoms may exacerbate
following delivery [27]. Furthermore, there is a link be-
tween RA, premature birth, and low birth weight- factors
that could have long-term implications for the child’s health
[28]. Previous research has identified some of the parenting
challenges women with chronic conditions experience,
however, little is known about how women with RA make
motherhood decisions [11]. It is therefore important that
the clinicians discuss with women fertility, pregnancy, and
lactations in the context of RA and its treatment, and con-
vey risks and benefits of different options. One approach
to facilitating such communication is to provide support
for both clinicians and patients, via accessible and targeted
educational material in a form of a decision aid tool.
Decision aids (DAs) are based on a well-developed,
evidenced-based approach to assisting individuals with
making health treatment and screening decisions [29, 30].
The development of DAs is commonly guided by the
International Patient Decision Aid Standards (IPDAS)
[31]. DAs support active participation in decision making
by weighing up the benefits and harms of treatment
options based on comprehensive, specific and relevant
information [29, 32] from unbiased, nondirective, current
research evidence [33].
Results of a comprehensive systematic review based on
55 randomized controlled trial and over 500 DAs con-
ducted by O’Connor and colleagues [34] have found
support for the effectiveness of those aids. Stacey et al
[32] conducted a recent update of this seminal work to
include 115 randomized controlled trials (n = 34,444) of
DAs. Some of the reviewed DAs refer to decisions re-
garding pregnancy and birthing options [33]; childbirth
options [35, 36], infertility issues [37], miscarriage [38],
pregnancy termination [39], and prenatal testing [40].
Another recent systematic review also found positive
effects of DAs on informed decision making in pregnancy
care, including increased knowledge, and decreased deci-
sional conflict and anxiety [33]. Currently, there is only
one published study of a DA on motherhood choices for
women with a chronic condition (Multiple Sclerosis) [41].
This paper reports on the randomized controlled study
that was conducted to evaluate the effectiveness of a DA
developed for women with RA [42]. It was hypothesised
that, based on previous DA studies, this DA would (1)
increase relevant knowledge and decrease decisional con-
flict (primary outcomes), and (2) not effect motherhood




This study was approved (H6884) by the Western Syd-
ney University Human Ethics Committee and conducted
according to the Helsinki ethical principles of research.
All participants provided written informed consent and
were not compensated for their participation.
Patients and methods
The reporting of this randomized controlled study was
informed by the CONSORTguidelines [43]. Eligible women
were those (i) aged within their child bearing and rearing
years that (ii) had been clinically diagnosed with RA and
currently under the care of a rheumatologist, and (iii)
contemplating having children or more children. No other
inclusion or exclusion criteria were applied. One hundred
and eighty-eight women enrolled in the study and were
randomly allocated to the intervention (DA) or no inter-
vention (control) group (Fig. 1). Of those, 167 women
(89 %) completed the pre-intervention questionnaire and
144 women (86 %) the post-intervention questionnaire.
Overall, 76 % of women initially enrolled in the study
completed both pre- and post-intervention questionnaires.
Recruitment took place over a 12-month period via
online advertising including a Google ad campaign, so-
cial media, media releases, website content and relevant
Arthritis websites, and print advertising including general
practitioner newsletters, posters, and flyers distributed
to rheumatology clinics. As women provided consent, a
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member of the research team randomly allocated them
to either the DA or control group, using the Bernoulli
function in Excel. As a consequence of the random alloca-
tion, the control and intervention groups were not bal-
anced for parity or gravity. The pre- and post-intervention
questionnaires were completed online via SurveyMonkey.
Once women in the intervention (DA) group had
completed the baseline questionnaire, they were sent a
link to the electronic version of the DA via email or
SurveyMonkey, and were asked to read it within two
weeks. All women in the sample possessed an active
email account and preferred the DA to be emailed rather
than mailed to them. Women in both groups were
followed up via phone or emailed approximately two to
four weeks after the baseline questionnaire. All women in
the intervention group were asked if they had read and
understood the DA, and had any questions or feedback
about the DA or the study topic. Women in the control
group were contacted and asked if they had any questions
or feedback about the questionnaire or study topic. Once
follow-up contact had been made, women in both groups
were sent a link to the post-intervention questionnaire via
SurveyMonkey. The questionnaire was identical to the one
completed in the pre-intervention phase except for the ex-
clusion of demographic questions. Non-respondents were
followed up via phone or email. The process of completing
pre and post surveys ranged between four to 12 weeks.
Measures
The demographic questions included: age, education,
marital status, country of birth, RA duration, number
of children, and pregnancy status. Participants were also
asked whether they wanted children prior to the RA diag-
nosis, if the diagnosis of RA complicated their decision to
have children (Yes, No, or Unsure), and how certain they
were in wanting children in the future (decision certainty)
(-5, Definitely would not have children, to +5, Definitely
would have children and a score of 0 indicating unsure).
Primary outcome measures
The Pregnancy in Rheumatoid Arthritis Questionnaire
(PiRAQ) was developed to assess the RA, pregnancy, and
parenting knowledge. Its items correspond directly to the
DA content including questions relating to general know-
ledge about RA, the physical and psychosocial effects of
RA, effects of RA on fertility and pregnancy, the effects of
RA medicines during conception, pregnancy, and breast-
feeding, postnatal considerations, and parenting with DA.
Scale development experts were consulted in the develop-
ment of items, and the final selection was based on pilot
results. The PiRAQ was piloted with a consumer sample
(women with RA and partners) (n = 17). Based on the pilot
results the number of items was reduced from 50 to 39 as
some lacked discriminatory power. The scores for PiRAQ
are calculated by summating the number of correct
Fig. 1 CONSORT flow-chart
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responses, and range between 0 and 39 with higher
scores indicating greater knowledge. In this study, the
PiRAQ’s internal consistency coefficient was 0.83.
Decisional conflict scale (DCS) [44]
The DCS is a 16-item self-report questionnaire which
measures personal perceptions of: (1) uncertainty in
health-related decision making; (2) factors contributing
to the uncertainty and; (3) the perceived effectiveness of
decision making. It consists of five subscales: informed,
values clarity, uncertainty, support, and effective decision.
The scale includes five response criteria ranging from
Strongly Agree (0) to Strongly Disagree (4) with scores ran-
ging from 0 (no decisional conflict) to 100 (extremely high
decisional conflict) [44]. The scale has good test-retest re-
liability (0.81) and internal consistency coefficients range
from 0.78-0.89 [44] and in this study was 0.95.
Secondary outcome measures
Arthritis self-efficacy scale (ASES) [45]
The ASES provides a measure of the patient’s perceived
ability to control and manage a number of aspects of
their arthritis [45]. A short form of the original ASES
was used in this study [46]. It contains eight items from
the original scale and has been validated [47]. Scores
range from 1-10 with higher scores indicating higher
levels of self-efficacy. Internal consistency for the short
form of the ASES has been reported above 0.90 [46, 47]
and in this study was 0.91.
The hospital anxiety and depression scale (HADS) [48]
The HADS consists of 14 items related to feelings of
anxiety (7 items) and depression (7 items). Responses
are scored from 0-3, with 3 indicating higher symptom
frequencies [49]. Scores may be calculated for each
subscale (anxiety and depression) and range from 0-21,
with clinical cut off for possible anxiety or depression be-
ing a score of 8-10 and probable indication being a score
of 11 and over. The scale’s internal consistency coefficients
exceed 0.80 [48] and in this study were 0.85. HADS is re-
ported to be suitable for the use with RA populations [50].
Decision aid
Motherhood choices: decision Aid for women with
rheumatoid arthritis
Development of the DA was conducted based on the
Ottawa Decision Support Framework and following the
guidelines of the IPDAS Collaboration [31]. Initial content
for the DA was devised based on areas of need identified
in the literature. It was then further informed with input
from consumer (i.e. women with RA) and expert (i.e.
rheumatologists, researchers, health care professionals)
panels (n = 33). The DA was delivered to the panels via an
online survey, with questions pertaining to: content, clarity/
readability, balance of information, structure/presentation,
and the option to provide qualitative feedback. Panel mem-
bers also met face-to-face within an advisory committee as
part of the feedback gathering process. Statements that
were agreed upon by 80 % of the panels’ members were
retained, and those with lower agreement rate were revised.
Consumer panel members and participants in the pilot
study contributed their experiences (‘women’s stories’) to
the DA. Pilot testing of the DA, as with the PiRAQ, was
conducted with a sample of 17 consumers. In addition to
participants completing a battery of questionnaires, they
also received a draft version of the DA to comment on its
content, clarity, balance of information, and structure. A re-
vised version of the DA was then reviewed by another panel
of experts (n = 5). Lastly, the Flesch-Kinkaaid readability
test was used to ensure that the DA text met the general
population’s reading age.
The final DA is a 45-page resource available in electronic
or paper versions, and contains three distinct sections: 1)
Information on RA, conception, pregnancy, and parenting;
2) decision making activities; and 3) resources. It provides
information about RA and its effects, the impact of RA and
medications on conception, pregnancy and motherhood,
the impact of pregnancy on RA, and ‘women’s stories’.
The DA also contains worksheets to assist women in
the decision making process (a decision tree, pros/cons
scales, support networks, a knowledge checklist, and note
taking). The DA is available online on the Arthritis NSW
website, http://arthritisnsw.org.au/arthritis/research/ra-and-
motherhood/ and is listed on the Ottawa Hospital Research
Institute’s Patient Decision Aids website: http://decisionai-
d.ohri.ca/AZsumm.php?ID=1787. The DA is currently be-
ing reviewed based on recent relevant literature.
Statistical analysis
Analyses were conducted using IMB SPSS Statistics (21.0),
with statistical significance set at p < .05 (two-tailed). Inde-
pendent t-tests and ANOVAs were used to assess differ-
ences between groups and across time. DAs are reported
to increase knowledge by 19 points, and reduce decisional
conflict by nine points [51]. A sample size of 130 subjects
is sufficient to detect moderate effects (0.13) [52] on each
of these differences with 95 % power at a 0.05 level of
significance [53]. According to Cohen’s specifications for
ANOVA analyses small, medium, and large effect sizes are
classified as 0.02, 0.13, and 0.26 respectively [52].
Results
A total of 188 women consented to participate in the
study. Forty-four (28 DA; 16 Control) participants did not
complete pre or post questionnaire and after a number of
efforts to contact them, were assumed to have withdrawn
from the study. The final sample of 144 participants con-
sisted of 78 women (mean age 31.26, SD =4.26) in the DA
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group, and 66 women (mean age 30.67, SD = 5.38) in the
control group. There were no significant differences on
demographic data between women in the DA group,
and women in the control group. Demographic data is
presented in Table 1.
Independent samples t-tests revealed no significant
differences between the DA and control groups on the
PiRAQ, t(142) = 1.642, p = 0.103, DCS t(142) = 1.614,
p = 0.109, HADS-A t(142) = 1.338, p = 0.183, HADS-D
t(142) = 0.764, p = 0.446,, or on RA-Complicated Decision,
t(142) = 1.156, p = 0.250 at baseline.
The 2 x 2 mixed between-within subjects ANOVA was
conducted to assess the impact of the DA on women’s
scores on the PiRAQ, DCS, ASES, HADS-A, and HADS-
D, and questions measuring RA-Complicated Decision
and Decisional Certainty at follow up (post intervention)
(Table 2). Participants in the DA and control groups both
had moderate knowledge at pre-intervention, with control
group scores remaining unchanged, and the DA group
increasing to moderate to high knowledge at post-
intervention. Both groups reported relatively low levels
of decisional conflict at pre-intervention; however the
DA group reported significantly lower decisional conflict
at post-intervention. Participants in both groups reported
moderate self-efficacy, high levels of anxiety symptoms
and low levels of depression symptoms.
Primary outcomes
Post-intervention scores on the PiRAQ, revealed a sig-
nificant time by group interaction, F(1, 141) = 38.474,
p < 0.001, ƞp2 = 0.214 (moderate to large effect size), in-
dicating larger improvement in knowledge in the DA
group compared to the control group. There was also
a significant main effect for group, F(1, 141) = 20.787,
p < 0.001, ƞp2 = 0.128 (moderate effect size). Therefore
knowledge improved across both groups, but was sig-
nificantly greater in the DA group.
Decisional conflict (DCS) also reduced significantly more
in the DA group than the control group, as indicated by a
time by group interaction, F(1, 142) = 18.794, p < 0.001,
ƞp2 = 0.117 (moderate effect size). Significant interaction
effects were found for three of the four DCS subscales:
‘informed’, ‘values clarity’, and ‘uncertainty’ with all inter-
action effects being Fs ≥ 5.28, ps ≤ 0.023, ƞp2 ≥ 0.036. There
was no main effect for group F(1, 141) = 0.002, p = 0.967,
ƞp2 = 0.000 but there was a significant main effect for time
on the ‘support’ subscale, F(1, 142) = 6.719, p = 0.011,
ƞp2 = 0.045. While the effect size was small, this indicates
that both the DA and control groups felt more supported
in their decision making from pre- to post-intervention.
Secondary outcomes
Anxiety did not change over time (HADS-A), F(1, 141) =
0.004, p = 0.947, ƞp2 = 0.000, nor differ between groups at
post-intervention, F(1, 141) = 1.411, p = 0.237, ƞp2 = 0.010
and there was no interaction effect, F(1, 141) = 0.520,
p = 0.472, ƞp2 = 0.004. Depression (HADS-D), also did not
significantly change over time F(1, 141) = 0.335, p = 0.552,
ƞp2 = 0.003, or between groups, F(1, 141) = 0.337, p = 0.562,
ƞp2 = 0.002 with no significant interaction effect, F(1, 141) =
0.500, p = 0.481, ƞp2 = 0.004.
Similarly, there was no significance difference between
RA-Complicated Decision from pre to post-intervention,
F(1, 142) = 1.415, p = 0.236, ƞp2 = 0.010 across time or
groups. Furthermore, the DA did not impact on women’s
decision certainty with no significant interaction or main
effects (all Fs ≤ 2.471, ps ≥ .152, ƞp2 ≤ .014) detected.
For arthritis self-efficacy (ASES), the main effects for
time F(1, 142) = .550, p = 0.460, ƞp2 = 0.004) and group
(F(1, 142) = 0.011, p = 0.917, ƞp2 < 0.001) were not signifi-
cant. However, there was a significant interaction effect,
F(1, 142) = 4.401, p = 0.038, ƞp2 = 0.030, indicating a post-
intervention increase for participants in the DA group,
although the effect size was small.
Table 1 Demographic data for 144 participants
Measures DA group Control group
54 % (n = 78) 46 % (n = 66)
Age (Yrs) 31.26 (4.26) 30.43 (5.07)
Education
Secondary Education (12 years) 8 % (n = 6) 10.8 % (n = 7)
Tertiary Education 92 % (n = 72) 88 % (n = 57)
Marital status
Single 10 % (n = 8) 15 % (n = 10)
Married 87 % (n = 68) 83 % (n = 54)
Divorced/separated 3 % (n = 2) 2 % (n = 1)
RA Duration in years 8.43 (6.97) 7.71 (7.19)
No. of children
0 65 % (n = 50) 69 % (n = 45)
1 26 % (n = 20) 23 % (n = 15)
2 9 % (n = 7) 6 % (n = 4)
Pregnant at time of survey 4 % (n = 3) 6 % (n = 4)
Wanted children before RA diagnosis
Yes 79 % (n = 61) 71 % (n = 46)
No 3 % (n = 2) 11 % (n = 7)
Unsure 18 % (n = 14) 18 % (n = 12)
Want to have (more) children in
the future
Definitely not 0 % (n = 0) 0 % (n = 0)
Unsure 51 % (n = 40) 38 % (n = 25)
Definitely yes 49 % (n = 38) 60 % (n = 39)
No significant differences were found on demographic data between women
in the DA and control groups
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Discussion
The aim of this randomized controlled study was to evalu-
ate the effectiveness of a DA resource tool developed for
women with RA when considering motherhood. In the DA
group knowledge increased by approximately 13 % and de-
cisional conflict decreased by 15 % compared to less than
1 % and 2 % respectively in the control group. Similar
changes in knowledge and decisional conflict were reported
in Prunty et al’s [41] study. While the knowledge increased
was lower than the average of 19 % across DA studies [51]
this may be due to the already high knowledge at the pre-
DA stage. The decisional conflict decline was, however,
considerably higher than the average improvement of nine
percent [32]. Importantly, the DA did not lead to any in-
creases in psychological distress (anxiety and depression).
This confirms that the DA is not associated with negative,
unintended consequences as also noted in Prunty et al’s
[41] study.
Despite careful attention to the methodology, a few
limitations remain, which should be taken into consider-
ation when interpreting the findings. Firstly, reliance on
self-selection, and drop out (which in this study was 44/188
participants) effects may have resulted in a sample that is
not representative of the broader population of women
with RA; particularly in relation to their high rates of
tertiary-education, relatively high level of knowledge about
RA and pregnancy, and low levels of decisional conflict.
Secondly, the evaluation of the knowledge pre and post DA
relied on a scale that was specifically developed for this
study, as there is no existing RA knowledge scale that
addresses pregnancy/parenthood related content, and
therefore had limited psychometric evaluation. Thirdly,
Table 2 Means, standard deviations, confidence intervals, and effect sizes for each outcome measure at pre and post intervention
DA group Control group ƞp2










PiRAQ 26.70 5.94 31.92 4.66 25.32 4.60 26.09 5.34 0.214**
(25.49-27.91) (30.80-33.05) (24.01-26.62) (24.88-27.31)
DCS 43.34 23.92 28.14 18.06 36.96 23.32 34.80 21.86 0.117**
(38.05-48.63) (23.69-32.59) (31.20-42.71) (29.96-39.64)
Informed 39.42 26.92 24.57 17.81 44.95 28.34 39.27 27.53 0.036*
(33.25-45.60) (19.47-29.67) (38.24-51.66) (33.72-44.81)
Values Clarity 36.54 25.56 25.32 19.62 32.07 27.44 31.06 26.13 0.051*
(30.62-42.46) (20.21-30.43) (25.64-38.50) (25.51-36.62)
Support 33.65 23.12 26.82 21.47 31.31 25.19 29.29 20.94 0.014*
(28.26-39.05) (22.06-31.57) (25.45-37.18) (24.13-34.46)
Uncertainty 49.89 27.87 40.06 28.52 43.81 28.92 44.82 30.79 0.049*
(43.55-56.24) (33.44-46.69) (36.91-50.72) (37.63-52.02)
Effective Decision 32.05 21.75 27.40 21.52 31.06 25.55 30.87 21.28 0.009
(26.78-37.33) (22.61-32.20) (25.33-36.80) (25.66-36.08)
Decision Certainty 3.72 1.66 3.51 1.87 3.91 1.72 3.74 1.76 0.014
(3.34-4.10) (3.11-3.92) (3.50-4.32) (3.30-4.19)
Complicated Decision 0.91 0.49 0.91 0.50 0.82 0.46 0.96 0.539 0.012
(0.80-1.02) (0.79-1.03) (0.70-0.93) (0.83-1.08)
ASES 5.43 1.87 5.81 1.92 5.74 2.00 5.56 2.03 0.030*
(5.00-5.86) (5.37-6.25) (5.27-6.21) (5.08-6.04)
HADS-A 8.87 3.73 8.71 3.77 8.00 3.66 8.14 4.13 0.004
(8.04-9.70) (7.82-9.59) (7.09-8.91) (7.17-9.10)
HADS-D 5.42 3.41 5.40 3.68 4.94 3.46 5.20 3.92 0.004
(4.65-6.19) (4.55-6.25) (4.10-5.78) (4.27-6.13)
*p-value < .05
**p-value < .001
CI Confidence Interval, PiRAQ: Pregnancy in Rheumatoid Arthritis Questionnaire, DCS Decisional Conflict Scale, ASES Arthritis Self-Efficacy Scale, HADS-A Hospital
Anxiety and Depression Scale- Anxiety, HADS-D Hospital Anxiety and Depression Scale- Depression
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the DA was self-administered and relied upon self-report
data. Fourthly, the short timeframe of the present study
means that the usefulness of the DA in actual decision
making was not established. Finally, whilst the findings
suggest this DA is a useful resource, its effectiveness in
face-to-face clinician-patient settings is yet to be evaluated.
These limitations notwithstanding, there are a number
of strengths of this study. Firstly, the development of the
DA was guided by, and aligned with, the IPDAS criteria
[31]. The DA was systematically developed in consultation
with both experts and consumers, which informed rele-
vance, clarity, balance, and readability of the DA. It was
then piloted and further refined before examining its ef-
fectiveness via a randomized controlled study. Lastly, the
effectiveness of the DA is consistent with findings of other
DAs across a range of health decisions [33, 35]. Given the
comparable findings of Prunty and colleagues [41] and the
current study it is likely that similar DAs could benefit
women with other chronic conditions.
Two issues, however, should be acknowledged. Firstly it
is important to note that as there are common concerns
and challenges across chronic conditions [11, 54], other
DAs may model the core features included in this DA,
while generic features, such as value clarifying exercises,
may be used in counselling settings [41]. Secondly, despite
some similarities, there are considerable differences across
chronic conditions (i.e. symptoms, subtypes, treatment,
progression, and prognosis). These factors may have
unique implications for fertility, pregnancy, and outcomes.
Therefore, the existing DAs should not be generalised to
motherhood decision making in other chronic conditions.
Given that having children is a decision that may be
revisited at different times, a longitudinal evaluation of the
impact of DAs is recommended [41] as well as further
evaluation of the DA’s usefulness, in terms of its compo-
nents (particularly in relation to treatment options), across
different populations and formats (i.e. briefer, interactive,
translated in other languages), and across settings (i.e. clin-
ical, counselling, etc.). Finally, the findings in this study
from the DCS’s subscales may be indicative of areas of the
DA that could be further strengthened when updating or
revising this resource.
Conclusions
In summary, a DA has been developed to support decision-
making for women with RA considering having children or
more children. The DA is consistent with the IPDAS cri-
teria, the gold standard for the development of decision
aids. This initial evaluation suggests that it is effective in
improving relevant knowledge and reducing decisional con-
flict without influencing women’s decisions or causing dis-
tress. This DA therefore has a direct application to patient
care in that it may facilitate communication and shared
decision making with family and health professionals.
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